脾静脉支架置入与脾动脉栓塞治疗左侧门静脉高压相关消化道出血临床结局的回顾性比较
本回顾性研究纳入37例左侧门静脉高压患者,比较脾动脉栓塞、脾静脉支架置入失败后即刻脾动脉栓塞及脾静脉支架置入三组的临床结局。脾静脉支架置入组再出血率7.1%(1/14)显著低于脾动脉栓塞与支架失败后栓塞组合并的47.8%(11/23)(p=0.01),因再出血行脾切除的比例两组间无显著差异(p=0.63),随访期间无介入操作相关死亡。作者认为脾静脉支架置入可行时安全有效,预防再出血似乎优于脾动脉栓塞。
要点
- 脾静脉支架置入组再出血率7.1%(1/14),显著低于脾动脉栓塞与支架失败后栓塞组合并的47.8%(11/23)(p=0.01)。
- 因再出血行脾切除的比例,脾静脉支架置入组7.1%(1/14)与合并组17.4%(4/23)无显著差异(p=0.63)。
- 随访期间各组均未观察到介入操作相关死亡。
诊断标准与关键数值
- 再出血(如呕血、黑便或两者兼有)在脾静脉支架置入组为7.1%(1/14),在脾动脉栓塞与脾静脉支架置入-脾动脉栓塞组合并为47.8%(11/23),差异有统计学意义(p=0.01)。
- 因再出血行脾切除在脾静脉支架置入组为7.1%(1/14),在脾动脉栓塞与脾静脉支架置入-脾动脉栓塞组合并为17.4%(4/23),差异无统计学意义(p=0.63)。
临床应用与阅片要点
- 作者认为脾静脉支架置入可行时是左侧门静脉高压相关消化道出血的安全有效治疗,预防再出血似乎优于脾动脉栓塞。
- 作者建议可能时优先推荐脾静脉支架置入而非脾动脉栓塞治疗左侧门静脉高压相关上消化道出血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Sinistral portal hypertension (SPH) is caused by an obstruction of the splenic vein and is a potential cause of upper gastrointestinal bleeding. Although splenic arterial embolization (SAE) and splenic vein stenting are accepted treatment options for SPH, their outcomes have not been compared directly. OBJECTIVE. This retrospective study compared the outcomes of splenic vein stenting and SAE for SPH-related gastrointestinal bleeding. METHODS. Data of patients with SPH treated by interventional radiology between January 1, 2013, and June 1, 2019, who had at least 6 months of clinical follow-up were retrospectively identified from the electronic database at our hospital. Patients were divided into the SAE group (SAE alone), splenic vein stenting-SAE group (SAE immediately after splenic vein stenting failure using the same procedure as the SAE group), and splenic vein stenting group (successful treatment with SVS). Patients' baseline characteristics and follow-up data were retrieved, and their clinical outcomes were compared. RESULTS. Thirty-seven patients with SPH were included. We assigned 11, 12, and 14 patients to the SAE, splenic vein stenting-SAE, and splenic vein stenting groups, respectively. Rebleeding (e.g., hematemesis, melena, or both) was significantly less common (p = .01) in the splenic vein stenting group (7.1% [1/14]) than in the SAE and splenic vein stenting-SAE groups combined (47.8% [11/23]). Splenectomy to resolve rebleeding was not significantly different (p = .63) in the splenic vein stenting group (7.1% [1/14]) compared with the SAE and splenic vein stenting-SAE groups combined (17.4% [4/23]). No interventional procedure-related deaths were observed during follow-up in any group. CONCLUSION. When feasible, splenic vein stenting is a safe and effective treatment of SPH-related gastrointestinal bleeding that appears to better prevent rebleeding than SAE. CLINICAL IMPACT. Splenic vein stenting should be recommended over SAE for the treatment of SPH-related upper gastrointestinal bleeding when possible.
引用
- Wei B, Zhang L, Tong H, et al. Retrospective Comparison of Clinical Outcomes Following Splenic Vein Stenting and Splenic Arterial Embolization in Sinistral Portal Hypertension-Related Gastrointestinal Bleeding. AJR Am J Roentgenol. 2020. PMID: 32845712. doi:10.2214/AJR.20.23859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。